(Q44053357)

29 November 2017

Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels (English)

1 reference

29 November 2017

1 reference

2

Paul M Ridker

1 reference

29 November 2017

Gavin J Blake

1

1 reference

PubMed ID

12103255

29 November 2017

Karen M Kuntz

series ordinal

3

1 reference

PubMed ID

12103255

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Journal of the American College of Cardiology

29 November 2017

1 reference

29 November 2017

40

1 reference

29 November 2017

49-55

1 reference

29 November 2017

1

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Effect of statins on C-reactive protein in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Coronary heart disease in residents of Rochester, Minnesota. VII. Incidence, 1950 through 1982

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

The multifactor primary prevention trial in Göteborg, Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Gains in life expectancy from medical interventions--standardizing data on outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

Expected gains in life expectancy from various coronary heart disease risk factor modifications

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901914-9

7 January 2021

10.1016/S0735-1097(02)01914-9

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

12103255